Aranesp is an Erythropoiesis Stimulating Agents (ESAs). ESAs are used to treat the blood-disorder anemia in patients with kidney failure or who are undergoing chemotherapy. The Food and Drug Administration warned that the drug increases death and accelerate tumor growth in patients with several types of cancer, including breast and cervical. Prior labeling added to the drugs in 2007 warned of similar risks in other types of cancers. The warnings apply to drugmaker Amgen's Aranesp and Epogen, as well as Procit, sold by Johnson & Johnson. Labeling approved by FDA said risks occurred when doctors treated patients with elevated levels of the drugs, which stimulate red blood cell levels.
Do not change medications without first consulting your doctor.